Journal article
Consensus Statement on Circulating Biomarkers for Advanced Prostate Cancer.
- Sumanasuriya S Institute of Cancer Research, Sutton, UK; The Royal Marsden Hospital NHS Trust, London, UK.
- Omlin A Cantonal Hospital St. Gallen, St. Gallen, Switzerland.
- Armstrong A Duke Cancer Institute, Duke University, Durham, NC, USA.
- Attard G Institute of Cancer Research, Sutton, UK; The Royal Marsden Hospital NHS Trust, London, UK.
- Chi KN BC Cancer Agency, Vancouver, BC, Canada.
- Bevan CL Imperial College London, London, UK.
- Shibakawa A Imperial College London, London, UK.
- IJzerman MJ University of Twente, Twente, The Netherlands.
- De Laere B Centre for Oncological Research, University of Antwerp, Antwerp, Belgium.
- Lolkema M Erasmus MC Cancer Institute, Rotterdam, The Netherlands.
- Lorente D Servicio Oncologia Medica Hospital Universitario La Fe, Valencia, Spain.
- Luo J James Buchanan Brady Urological Institute, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
- Mehra N Radboud University Nijmegen Medical Center, Nijmegen, The Netherlands.
- Olmos D Spanish National Cancer Research Centre, Madrid, Spain.
- Scher H Memorial Sloan Kettering Cancer Center, New York, NY, USA.
- Soule H Prostate Cancer Foundation, Santa Monica, CA, USA.
- Stoecklein NH University Hospital and Medical Faculty of the Heinrich-Heine University Düsseldorf, Düsseldorf, Germany.
- Terstappen LWMM University of Twente, Twente, The Netherlands.
- Waugh D Queen's University Belfast, Belfast, UK.
- de Bono JS Institute of Cancer Research, Sutton, UK; The Royal Marsden Hospital NHS Trust, London, UK. Electronic address: johann.de-bono@icr.ac.uk.
- 2019-05-18
Published in:
- European urology oncology. - 2018
Advanced prostate cancer
Androgen receptor splice variants
Cell-free DNA
Circulating biomarkers
Circulating tumour cells
Consensus
Biomarkers, Tumor
Cell-Free Nucleic Acids
Consensus
Delphi Technique
Early Detection of Cancer
Genomics
Humans
Male
Neoplastic Cells, Circulating
Prostatic Neoplasms
Treatment Outcome
English
CONTEXT
In advanced prostate cancer (PC), there is increasing investigation of circulating biomarkers, including quantitation and characterization of circulating tumour cells and cell-free nucleic acids, for therapeutic monitoring and as prognostic and predictive biomarkers. However, there is a lack of consensus and standardisation regarding analyses, reporting, and integration of results into specific clinical contexts. A consensus meeting on circulating biomarkers was held to address these topics.
OBJECTIVE
To present a report of the consensus statement on circulating biomarkers in advanced PC.
EVIDENCE ACQUISITION
Four important areas of controversy in the field of circulating biomarkers in PC management were identified: known clinical utility of circulating biomarkers; unmet clinical needs for circulating biomarkers in PC care; most pressing blood-based molecular assays required; and essential steps for developing circulating biomarker assays. A panel of 18 international PC experts in the field of circulating biomarkers developed the programme and consensus questions. The panel voted publicly but anonymously on 50 predefined questions developed following a modified Delphi process.
EVIDENCE SYNTHESIS
Voting was based solely on panellist opinions of the predefined topics and therefore not on a standard literature review or meta-analysis. The outcomes of the voting had varying degrees of support, as reflected in the wording of this article and in the detailed voting results provided in the Supplementary material.
CONCLUSIONS
The expert voting results presented can guide the future development of circulating biomarkers for PC care. Notably, the consensus meeting highlighted the importance of reproducibility and variability studies, among other significant areas in need of trials specifically designed to address them.
PATIENT SUMMARY
A panel of international experts met to discuss and vote on the use of different blood-based prostate cancer tests, and how they can be used to guide treatment and disease monitoring to deliver more precise and better patient care.
In advanced prostate cancer (PC), there is increasing investigation of circulating biomarkers, including quantitation and characterization of circulating tumour cells and cell-free nucleic acids, for therapeutic monitoring and as prognostic and predictive biomarkers. However, there is a lack of consensus and standardisation regarding analyses, reporting, and integration of results into specific clinical contexts. A consensus meeting on circulating biomarkers was held to address these topics.
OBJECTIVE
To present a report of the consensus statement on circulating biomarkers in advanced PC.
EVIDENCE ACQUISITION
Four important areas of controversy in the field of circulating biomarkers in PC management were identified: known clinical utility of circulating biomarkers; unmet clinical needs for circulating biomarkers in PC care; most pressing blood-based molecular assays required; and essential steps for developing circulating biomarker assays. A panel of 18 international PC experts in the field of circulating biomarkers developed the programme and consensus questions. The panel voted publicly but anonymously on 50 predefined questions developed following a modified Delphi process.
EVIDENCE SYNTHESIS
Voting was based solely on panellist opinions of the predefined topics and therefore not on a standard literature review or meta-analysis. The outcomes of the voting had varying degrees of support, as reflected in the wording of this article and in the detailed voting results provided in the Supplementary material.
CONCLUSIONS
The expert voting results presented can guide the future development of circulating biomarkers for PC care. Notably, the consensus meeting highlighted the importance of reproducibility and variability studies, among other significant areas in need of trials specifically designed to address them.
PATIENT SUMMARY
A panel of international experts met to discuss and vote on the use of different blood-based prostate cancer tests, and how they can be used to guide treatment and disease monitoring to deliver more precise and better patient care.
- Language
-
- English
- Open access status
- hybrid
- Identifiers
-
- DOI 10.1016/j.euo.2018.02.009
- PMID 31100240
- Persistent URL
- https://sonar.ch/global/documents/186499
Statistics
Document views: 31
File downloads: